SEC Form 4 · accession 0001140361-17-001260

OncoMed Pharmaceuticals Inc · OMED

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Paul J Hastings

Officer — Chairman & CEO · Director

Period of report

Jan 5, 2017

Accepted (ET)

Jan 9, 2017 · 5:55 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001302573

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Jan 5, 2017	M	21,369	$1.43	A	58,692	D
Common Stock^F3,F2	Jan 5, 2017	S	21,369	$8.1708	D	37,323	D
Common Stock^F2	Jan 6, 2017	M	21,369	$1.43	A	58,692	D
Common Stock^F4,F2	Jan 6, 2017	S	21,369	$8.515	D	37,323	D
Common Stock^F5	holding	—	—		—	324,840	I	See Footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F6	$1.43	Jan 5, 2017	M	21,369	D	—	Jan 11, 2017	Common stock	21,369	21,369	D
Stock Option (Right to Buy)^F6	$1.43	Jan 6, 2017	M	21,369	D	—	Jan 11, 2017	Common Stock	21,369	0	D

Explanation of responses

F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 30, 2016.
F2Includes 30,875 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
F3This transaction was executed in multiple trades in prices ranging from $8.06 to $8.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4This transaction was executed in multiple trades in prices ranging from $8.22 to $8.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5The shares are held by Paul J. Hastings & Steve N. De Jong, Trustors and/or TTEES, The Hastings-De Jong Lv Tr DTD May 1, 2012.
F6The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.